Two Complete Metabolic Responses (CMRs) observed in patients with relapsed/refractory metastatic Ewing sarcoma and one Complete Response (CR) ...
Actuate Therapeutics (ACTU) announced results from the phase 1 portion of its phase 1/2 clinical study evaluating elraglusib as a monotherapy or ...
As Chief Medical Officer of Syncromune, Dr. Dale will lead the clinical development of SYNC-T, provide strategic and medical oversight for the company’s expanding pipeline, and play a central role in ...
Asianet Newsable on MSN
Feeling constantly tired? It could be a sign of kidney tumours
Frequent health examinations and screening for people who discovers the symptoms on the early state, which helps to prevent ...
Recent advances in cancer biology have revealed that refractory malignancies, such as castration-resistant prostate cancer, pancreatic ductal ...
A large-scale international study, led by researchers from the Gray Faculty of Medical and Health Sciences at Tel Aviv ...
Ovarian cancer often goes undetected for a long time. In seven out of 10 patients, the tumor has already formed secondary ...
The discovery could pave the way for new treatments, improved risk prediction, and earlier intervention for brain metastases.
“We are encouraged by the emerging data from our lung cancer programs, where systemically delivered Olvi-Vec continues to ...
Immune checkpoint molecules play a crucial role in keeping the immune system in balance and preventing an attack on the ...
Interim data from 14 patients with progressive lung cancers in dose-escalation cohorts of systemically administered Olvi-Vec-primed ...
In a TNBC animal model with limited responsiveness to chemotherapy, Telomir-1 demonstrated statistically significant activity ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback